Making real world evidence fit for purpose

Although real world evidence (RWE) is a hot topic in pharma right now, many still question whether it is acceptable to be used in regulatory decision making. A new report says that while RWE can be transformative for drug assessment, there’s still a need to define the rules for what kinds of RWE can actually be useful to developers and regulators.